|
Attenuation of key pathways in systemic sclerosis: agents for evaluation |
|
| Candidate therapy |
Target pathway |
|
|
|
| Bosentan |
ETA/ETB pathway |
| Imatinib |
PDGF receptor signalling |
| signalling Infliximab |
TNF-α |
| Adalimumab |
TNF-α |
| Etanercept |
TNF-α |
| CAT-192 |
TGF-β1 |
| GC-1008 |
TGF-β1, TGF-β2, TGF-β3 |
| FG-3019 |
CTGF ligand |
| Alefacept |
LFA3/CD2 |
| Basiliximab |
IL-2Rα |
| MLM-1202 |
CCR2 |
| Efalizumab |
LFA/ICAM-1 |
|
CCR, CC chemokine receptor; ETA/B, endothelin receptor subtype A/B; CTGF, connective tissue growth factor; ICAM, intercellular adhesion molecule; IL-2Rα, interleukin-2 receptor α; LFA, lymphocyte function associated; PDGF, platelet-derived growth factor; TGF, transforming growth factor; TNF, tumour necrosis factor. | |
Denton Arthritis Research & Therapy 2007 9(Suppl 2):S6 doi:10.1186/ar2190 |
|